Statistically significant and anabolic or anti catabolic are very different things. As I pointed out you can double levels of our most anabolic hormones and it does absolutely noting for body composition.
Do I think its worth trying- yes. Do I think its prudent for people to assume or say what you are this early in the game - no freaking way. Your entitled to your opinion, Ill base mine on facts and data on humans. Hard data- not oh it does this so it should do that. Thinking like that has been proven time and time again to be totally false.
JMO
Also if I was going to run a GHRP in pct id also run a GHRH with it like mod grf to maximize the desired effects. Again , JMO....
The increase is both statistically significant and results in anabolic/anti-catabolic effects. I understand what you are trying to convey with your example regarding SERMS doubling Testosterone and having no effect on body composition, I'd love to see the studies on that by the way. But Testosterone and Growth Hormone/IGF-1 are two very different things as well. They may be anabolic, but the way in which they exert their anabolic effects are not the same. You cannot compare a SERM to a Growth Hormone Secretagogue. I really wouldn't say anything is being said 'this early in the game'. MK-677 has been around for quite sometime, as I stated, the data is out there. I agree, I am entitled to me opinion, and you are entitled to yours. Since you say you'll base your opinion on facts and data on humans, 'hard data', you seem to wish to imply that I do not. I was conveying facts taken from data on humans, which I would consider hard data. I am more than interested in seeing the facts/data on humans/hard data you form your opinion on that is counter to mine.
-It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including GH and insulin-like growth factor 1 (IGF-1), but without affecting cortisol levels in normal young men.
(Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism. 1996 Aug;81(8):2776-82. PMID 8768828)
-Human studies have shown it to increase both muscle mass and bone mineral density.
(Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. Journal of Bone and Mineral Research. 1999 Jul;14(7):1182-8. PMID 10404019)
(Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Journal of Clinical Endocrinology and Metabolism. 2001 Mar;86(3):1116–25. PMID 11238495)
-It increases growth hormone, fat-free mass (muscle and bone), and raises energy expenditure (resulting in fat loss).
(Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism. 1998 Feb;83(2):362-9. PMID 9467542)
-IGF-1 levels remain elevated in humans with a single oral dose for up to 24 hours.
(Smith, Roy G.; Ploeg, Lex H. T. Van der; Howard, Andrew D.; Feighner, Scott D.; Cheng, Kang; Hickey, Gerard J.; Wyvratt, Matthew J.; Fisher, Mike H.; Nargund, Ravi P.; Patchett, Arthur A. (1997). "Peptidomimetic Regulation of Growth Hormone Secretion". Endocrine Reviews (The Endocrine Society) 18 (5): 621–645. doi:10.1210/edrv.18.5.0316. Retrieved 2015-06-13.)